Score Overview
Explore the 2021 public Archive ranking →
Where ImmuCell Corporation has ranked, year by year
Showing 20 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ICCC
2010: 94.3% · 2021: 87.7% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 9.88 | — |
1 Year2025-09-26 | $ 6.03 | 63.85% |
5 Years2021-09-28 | $ 9.38 | 5.33% |
10 Years2016-09-28 | $ 7.98 | 23.81% |
20 Years2006-09-28 | $ 4.89 | 102.04% |
30 Years1996-09-27 | $ 3.13 | 216.16% |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 |
|---|---|---|---|---|---|---|
| Price | $ 9.88 | $ 6.03 | $ 9.38 | $ 7.98 | $ 4.89 | $ 3.13 |
| Return | — | 63.85% | 5.33% | 23.81% | 102.04% | 216.16% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 29M | -$ 545.4K | $ 6M |
| 2025 | $ 27M | -$ 1M | $ 3M |
| 2024 | $ 26M | -$ 2M | $ 3M |
| 2023 | $ 17M | -$ 5M | $ 978.74K |
| 2022 | $ 18M | -$ 2M | $ 5M |
| 2021 | $ 19M | -$ 78.29K | $ 10M |
| 2020 | $ 15M | -$ 1M | $ 7M |
| 2019 | $ 13M | -$ 1M | $ 8M |
| 2018 | $ 10M | -$ 2M | $ 2M |
| 2017 | $ 10M | -$ 168K | $ 3M |
| 2016 | $ 9M | $ 508.45K | $ 10M |
| 2015 | $ 10M | $ 1M | $ 6M |
| 2014 | $ 7M | -$ 167.16K | $ 3M |
| 2013 | $ 6M | $ 117.39K | $ 5M |
| 2012 | $ 5M | $ 89.51K | $ 4M |
| 2011 | $ 5M | -$ 409.51K | $ 4M |
| 2010 | $ 4M | -$ 384.68K | $ 4M |
| 2009 | $ 4M | -$ 216.49K | $ 4M |
| 2008 | $ 4M | -$ 468.56K | $ 5M |
| 2007 | $ 6M | $ 662.14K | $ 5M |
| 2006 | $ 4M | $ 647.14K | $ 6M |
| 2005 | $ 4M | $ 707.78K | $ 5M |
| 2004 | $ 3M | $ 143.52K | $ 4M |
| 2003 | $ 3M | $ 411.22K | $ 4M |
| 2002 | $ 6M | $ 886.24K | $ 3M |
| 2001 | $ 6M | $ 420K | $ 1M |
| 2000 | $ 5M | $ 2M | $ 1M |
| 1999 | $ 4M | $ 550.84K | $ 1M |
| 1998 | $ 4M | -$ 100K | $ 1M |
| 1997 | $ 4M | $ 300K | $ 1M |
| 1996 | $ 4M | -$ 100K | $ 1M |
| 1995 | $ 4M | $ 1M | |
| 1994 | $ 4M | -$ 100K | $ 1M |
| 1993 | $ 3M | $ 1M | |
| 1992 | $ 3M | -$ 200K | $ 1M |
| 1991 | $ 2M | -$ 1M | $ 800K |
| 1990 | $ 3M | -$ 600K | $ 900K |
| 1989 | $ 2M | -$ 1M | $ 600K |
ImmuCell Corporation fundamental performance
Between 2020 and 2025, revenue grew from $ 15M to $ 27M and net income went from -$ 1M to -$ 1M. Revenue increased in 3 of those 5 years; net income in 3.
Across ImmuCell Corporation's full reported history, from 1989 to 2025, revenue grew from $ 2M to $ 27M and net income went from -$ 1M to -$ 1M. Revenue increased in 68% of the years measured; net income in 55%.
ImmuCell Corporation currently holds a 20-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.
Membership
Continue ICCC’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
